GlassScriptPhysician profile
Ashish K Vala
NPI 1225267412
$2,253.59
in general payments reported to CMS, 2019-2025
31 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $299 · 2021: $562 · 2022: $195 · 2023: $603 · 2024: $155 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Travel and Lodging: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.35 |
| Travel and Lodging | $127.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $502.65 | 2019-2023 | Enbrel, Otezla, Evenity |
| Pacira Pharmaceuticals Incorporated | $251.72 | 2023-2024 | Iovera, Zilretta, Exparel |
| Ucb, INC. | $228.69 | 2019-2023 | Cimzia |
| Arbor Pharmaceuticals, INC. | $182.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $162.98 | 2019-2021 | |
| Depuy Synthes Sales INC. | $132.46 | 2019-2025 | Orthovisc, Monovisc |
| Fidia Pharma USA INC. | $95.44 | 2021-2025 | Hymovis |
| Bioventus LLC | $89.74 | 2019-2025 | Durolane, Gelsyn-3 |
| Ferring Pharmaceuticals INC. | $70.81 | 2021-2024 | Euflexxa |
| Astrazeneca Pharmaceuticals LP | $54.18 | 2021-2022 | |
| Ethicon US, LLC | $42.03 | 2023 | N/A |
| Horizon Therapeutics Plc | $41.88 | 2019-2022 | |
| Moximed, INC | $40.53 | 2025 | Misha Knee System, Small, Left |
| Pfizer INC. | $30.78 | 2020 | |
| Pacira Therapeutics, INC. | $29.88 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $23.96 | 2023 | Teriparatide |
| Alexion Pharmaceuticals, INC. | $23.36 | 2023 | Strensiq |
| Endo Pharmaceuticals INC. | $22.82 | 2023 | Xiaflex |
| Kiniksa Pharmaceuticals, LTD. | $22.11 | 2023 | Arcalyst |
| Teleflex LLC | $21.38 | 2023 | Urolift |
| Lilly USA, LLC | $19.63 | 2022 | |
| Abbvie INC. | $18.46 | 2023 | Rinvoq |
| Radius Health, INC. | $18.36 | 2021 | |
| Zimmer Biomet Holdings, INC. | $18.34 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Janssen Biotech, INC. | $17.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.08 | 2021 | |
| Ibsa Pharma INC. | $16.96 | 2023 | Licart, Tirosint |
| Kyowa Kirin, INC. | $15.98 | 2024 | Crysvita |
| Avanos Medical | $14.50 | 2024 | Trivisc Sodium Hyaluronate |
| Azurity Pharmaceuticals, INC. | $13.89 | 2024 | Horizant |
| Kowa Pharmaceuticals America, INC. | $12.80 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Vala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.